At ASH, new data from the MonumenTAL-1 trial that underpins that filing showed that subcutaneous talquetamab achieved an overall response rate (ORR) of 74% at a 0.4 mg/kg dose and 73% at a 0.8 mg ...

Ars Technica has been separating the signal from the noise for over 25 years. With our unique combination of technical savvy and wide-ranging interest in the technological arts and sciences, Ars ...

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.